Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Regression of liver metastases in patient with gastrin-secreting tumour treated with SMS 201-995.

× No keyword cloud information.

12 in total

1. The treatment of neuroendocrine tumors with long-acting somatostatin analogs: a single center experience with lanreotide autogel.

Authors: A Bianchi; L De Marinis; A Fusco; F Lugli; L Tartaglione; D Milardi; M Mormando; A P Lassandro; R Paragliola; C A Rota; S Della Casa; S M Corsello; M G Brizi; A Pontecorvi
Journal: J Endocrinol Invest Date: 2011-11-07 Impact factor: 4.256

Review 2. Antitumor effects of somatostatin analogs in neuroendocrine tumors.

Authors: Lucas Sidéris; Pierre Dubé; Anja Rinke
Journal: Oncologist Date: 2012-05-24

Review 3. Somatostatin.

Authors: S R Bloom; J M Polak
Journal: Br Med J (Clin Res Ed) Date: 1987-08-01

Review 4. Somatostatin and analogues in the treatment of cancer. A review.

Authors: B M Evers; D Parekh; C M Townsend; J C Thompson
Journal: Ann Surg Date: 1991-03 Impact factor: 12.969

5. Somatostatin analogue octreotide and inhibition of tumour growth in metastatic endocrine gastroenteropancreatic tumours.

Authors: R Arnold; M E Trautmann; W Creutzfeldt; R Benning; M Benning; C Neuhaus; R Jürgensen; K Stein; H Schäfer; C Bruns; H J Dennler
Journal: Gut Date: 1996-03 Impact factor: 23.059

Review 6. Use of octreotide acetate for control of symptoms in patients with islet cell tumors.

Authors: P N Maton
Journal: World J Surg Date: 1993 Jul-Aug Impact factor: 3.352

7. Somatostatin analog sandostatin and inhibition of tumor growth in patients with metastatic endocrine gastroenteropancreatic tumors.

Authors: R Arnold; C Neuhaus; R Benning; W B Schwerk; M E Trautmann; K Joseph; C Bruns
Journal: World J Surg Date: 1993 Jul-Aug Impact factor: 3.352

8. Long acting somatostatin treatment of paraneoplastic Cushing's syndrome in a case of Zollinger-Ellison syndrome.

Authors: P Ruszniewski; F Girard; R Benamouzig; M Mignon; S Bonfils
Journal: Gut Date: 1988-06 Impact factor: 23.059

Review 9. Octreotide. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in conditions associated with excessive peptide secretion.

Authors: P E Battershill; S P Clissold
Journal: Drugs Date: 1989-11 Impact factor: 9.546

Review 10. Current diagnosis and management of Zollinger-Ellison syndrome.

Authors: D K Andersen
Journal: Ann Surg Date: 1989-12 Impact factor: 12.969